Objective To assess the efficacy and safety of treating irritable bowel syndrome (IBS) of liver stagnation type with Tongxie Yaofang.Methods:To collect RCTs of treating IBS with Tongxie Yaofang by computer from databases include CBM,CNKI,VIP,WANFANG,EMbase,PubMed and Cochrane Library.The date is from the founding time of the database to December 2015.The RCTs were chosen independently,data was extracted and the quality was evaluated and cross checked by two researchers,using Review Manger 5.3.3 software,produced by Cochrane.Results:A total of 26 trials were included with 2694 patients.Funnel plot is asymmetric distribution,suggesting that there may be a publication bias or inclusion in the study method of low quality.Meta analysis results show that Tongxie Yaofang can improve clinical symptoms of liver stagnation and spleen deficiency in patients with IBS and had higher total effective rate than the control medicine ［Total efficiency rate OR=5.16,95%CI (4.05,6.58); Cure rate OR=2.75，95%CI (2.24,3.36)］.The incidence of adverse events in the 9 groups was significantly lower than that of the control group.The recurrence rate of the 4 groups was lower than that of the control group［recurrence rate OR=0.29,95% CI(0.14,0.61)］.Conclusion:Tongxie Yaofang has obvious effect in the treatment of liver stagnation and spleen deficiency type of IBS.However,due to the low methodological quality of included studies and possible publication bias,the above conclusions need to be further proved with large sample,high quality and multi center randomized double blind controlled trials.